In 2018, approximately 5.7 million Americans are living with Alzheimer’s dementia, a number that is expected to double within the next 30 years. Alzheimer’s disease causes memory loss, mood changes, and eventually difficulty speaking, swallowing, and walking. Currently, no medication exists that can slow or stop the progression of Alzheimer’s disease and no new treatments have been approved by the FDA in more than 15 years.

On July 25th, Eisai Co. Ltd. and Biogen Inc. presented positive results from a Phase 2 clinical trial testing the new Alzheimer’s drug BAN2401. The trial included 856 patients with mild Alzheimer’s disease who received the drug, which targets a protein called β-amyloid. When β-amyloid folds into the wrong shape, it sticks together and forms plaques around neurons, blocking their ability to communicate. BAN2401 binds to the components of these plaques and promotes their clearance.

Twelve months into the treatment, the drug initially produced disappointing results; however, at 18 months, 161 patients (those receiving the highest dose) showed a reduction in amyloid plaques. These patients also exhibited a 30% slower cognitive decline, making BAN2401 the first drug to improve brain function. There are caveats to consider: Patients with a gene called APOE4, which has been associated with accelerated cognitive decline, were excluded from this treatment group due to a predisposition to drug-induced brain swelling. This prompts us to question whether the drug will be effective in all patients. We are both excited —and cautious— as we await the Phase 3 clinical trial results.

Managing Correspondent: Jeremy Gungabeesoon

Press Release:

Eisai And Biogen Announce Detailed Results Of Phase II Clinical Study Of BAN2401 In Early Alzheimer’s Disease At Alzheimer’s Association International Conference (AAIC) 2018

New Alzheimer’s drug shows hints of promise in inventive trial

Clinical Trial (National Institute on Aging/National Institutes of Health):

BAN2401 for Early Alzheimer’s Disease

A Study to Evaluate Safety, Tolerability, and Efficacy of BAN2401 in Subjects With Early Alzheimer’s Disease

Photo Credit: Image courtesy of National Institute on Aging, National Institutes of Health, U.S. Department of Health and Human Services.

15 thoughts on “Hope for Alzheimer’s patients? The first positive clinical trial results in years

  1. At age 62, I have noticed greatly increasing symptoms of dementia over probably the last ten years,i notice an increasing confusion, mood swings, and of course, forgetfulness. It has gotten so bad, I cannot trust myself to even do simple things. And, of course, this realization causes even more depression and anxiety. I had no choice but to seek another alternative choice online . I am a retired fire captain/paramedic, and am married to a registered nurse,we decided to try multivitamin herbal formula due to their success rate of their  Alzheimer’s herbal treatment. I use the herbal remedy in 2018 ,the herbal cure has successfully get rid of my Alzheimer’s condition with all symptoms I was experiencing.The herbal cure surprised my wife and anyone who knew me battling with it, there is a cure for Alzheimer’s disease at there ,people still suffer from it due to lack of information .I highly recommend w w w multivitamincare. org treatment for those who know the feeling of suffering from these conditions. 

    1. Quitting gluten did it for me. I couldn’t walk into another room without forgetting why I walked in there. It takes 30 days to clean the body of gluten toxicity. After that, I can switch rooms and still remember why I did. Good luck to everyone!

  2. If it’s not too much trouble, let me know how my relative with Alzheimer’s can get this prescription or get into another examination. Additionally let me know about any advances that could help moderate and additionally improve her mind work.

    1. I invented a toothbrush in 2006 with a 450nm royal blue high-power LED in the brush head. We tested at GSK in London and found out that this frequency penetrates tooth enamel, bone and gum tissue, killing 100% of the P. Gingivalis bacteria. This bacterium is suspected to cause Alzheimer’s. I am currently building a device to kill the bacteria in the brain. If you want to know more please reply.

Leave a Reply

Your email address will not be published. Required fields are marked *